ArticleJournal of gastrointestinal cancer2026
Nationwide Practice Patterns of Early Postoperative Kampo Medicine after Gastrectomy for Gastric Cancer: A Japanese Administrative Database Study.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeKampo medicines are incorporated into early postoperative supportive care in Japan, but nationwide real-world data after gastrectomy are limited. We characterized early postoperative use of Daikenchuto and Rikkunshito and explored postoperative length of stay (LOS) as a secondary descriptive outcome.
methodsUsing a Japanese Diagnosis Procedure Combination administrative database from 472 hospitals (August 2017-July 2022), we identified adults undergoing gastrectomy for gastric cancer. Early postoperative use was defined as administration within 7 postoperative days. Prescription rates were compared by hospital characteristics and surgical procedure (open vs. laparoscopic distal, total, and proximal gastrectomy). Postoperative LOS was calculated from surgery to discharge.
resultsAmong 26,097 eligible patients, 1,797 (6.9%) received Daikenchuto and 2,309 (8.8%) received Rikkunshito. Daikenchuto was more frequently used after open than laparoscopic surgery (8.3% vs. 5.7%) and was most often prescribed after open distal (8.9%) and open total gastrectomy (7.6%). Rikkunshito was more frequently prescribed in designated cancer hospitals and large hospitals (≥500 beds), and after distal or proximal gastrectomy than total gastrectomy (9.6% vs 6.3%). The median postoperative LOS was 12 days among Daikenchuto users versus 11 days among non-users, and 10 days among Rikkunshito users versus 11 days among non-users.
conclusionEarly postoperative Kampo prescribing after gastrectomy differed across institutions and surgical procedures. The principal finding of this study was nationwide variation in prescribing patterns. Postoperative LOS differed descriptively between users and non-users, although these comparisons were unadjusted and subject to substantial time-dependent and clinical confounding.
Indexed as
Identifiers
42599543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.